Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Eli Lilly has seized 60% of the GLP-1 obesity drug market, cementing its dominance over Novo Nordisk in a duopoly that controls 87% of the segment. The performance gap has widened dramatically: LLY shares are up 58% over the past 52 weeks, while NVO has collapsed 62% since July 2024.

The divergence reflects execution in a market expected to nearly double from $66 billion in 2025 to $120 billion by 2030. Lilly's larger share of that growth has driven investor preference, leaving Novo's weaker positioning reflected in its stock decline.

Novo recently launched a pill-form obesity drug that could alter competitive dynamics. The oral delivery format may appeal to patients avoiding injections, potentially chipping away at Lilly's lead if uptake accelerates.

The 60% versus 40% market share split now embedded in the stocks creates a clear benchmark for reassessing momentum. Any meaningful shift in prescription trends or market-share data will signal whether Novo's pill offering can reverse its slide or if Lilly's dominance continues to widen.